SHARP PLASMACLUSTER TECHNOLOGY HAS BEEN TESTED AND SHOWN TO DECREASE THE RISK OF TB INFECTION IN TB HOSPITAL FOR THE 1ST TIME.

SHARP PLASMACLUSTER TECHNOLOGY HAS BEEN TESTED AND SHOWN TO DECREASE THE RISK OF TB INFECTION IN TB HOSPITAL FOR THE 1ST TIME.

In a world’s first groundbreaking study, SHARP’s Plasmacluster technology has been tested and shown to decrease the risk of Tuberculosis (TB) infection by a significant degree.

SHARP has collaborated with the World Health Organization (WHO) Global Health Workforce Alliance National Center of Tuberculosis and Lung Disease in Tbilisi, Georgia, to conduct a Plasmacluster technology effectiveness test on healthcare workers and TB patients.

The results showed a 75%*1 decreased risk of TB infection among healthcare workers and a 78%*2 prevention of Acquired Drug Resistance on TB patients by comparing subjects with and without exposure to specially designed Plasmacluster Ion Generators emitting 100,000 ions/cm3.

SHARP’s Plasmacluster has already been proven to effectively suppress virus, bacteria, mould, odour, allergens, and other infectious viruses.


Reference :

1. Results of reduced risk of tuberculosis infection for healthcare workers88 healthcare workers were tested for Tuberculosis bacteria using QuantiFERON-TB Gold In-Tube (QFT)*3. 32 of the healthcare workers who did not carry the bacteria were tested again after 6-8 months using QFT test. Healthcare workers in the 100,000/cm3 PCI device setting decreased their risk of getting latent Tuberculosis infection by 75% compared with those who were not in the PCI device setting.

2. Prevention of Acquired Drug Resistance in Tuberculosis Hospital Patients155 Tuberculosis culture positive patients in the Drug Sensitive department received the Drug Susceptibility Testing (DST)*4. After a 3 months period, 49 patients who remained culture positive received DST again. Those who were in the 100,000/cm3 PCI device setting showed 78% of prevention in acquired drug resistance compared to those who were not in the PCI device setting.

3. QuantiFERON-TB Gold In-Tube is a test for detection Latent Tuberculosis Infection (LTBI) using a blood sample. It came into use in 2007.

4. Drug Susceptibility Testing is a test used to determine which medicine to administer to patients who carry the tuberculosis bacteria.